Evidence map›Paper›PMID 40635031›Full record

ArticleWorld journal of surgical oncology2025

UBC9 overexpression promotes proliferation and metastasis in gastric cancer via ATF2.

QingShui Wang, ShengZhao Li, YiNing Xu, Yuluo Chen, Chao Xu, QiuYan He, Yan Ye, YiMin Huang, Yue Wu, KeJia Guo and 9 more

Abstract read
In one paragraph

Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Ubiquitin-conjugating Enzymes in Cancer.International journal of biological sciences · 2026
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

QingShui Wang *The Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, College of Integrative Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China. wangqingshui@fjtcm.edu.cn.
ShengZhao Li *College of Life science, Fujian Normal University, Fuzhou, Fujian, China.
YiNing Xu *The Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, College of Integrative Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
Yuluo Chen *College of Life science, Fujian Normal University, Fuzhou, Fujian, China.
Chao Xu *Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.
QiuYan He *Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.
Yan Ye *Ganzhou Key Laboratory of Molecular Medicine, the Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, 341000, Jiangxi, China.
YiMin HuangThe Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, College of Integrative Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
Yue WuThe Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, College of Integrative Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
KeJia GuoThe Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, College of Integrative Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
YaJuan WeiThe Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, College of Integrative Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
Yide HuangCollege of Life science, Fujian Normal University, Fuzhou, Fujian, China.
Yan LiuThe Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, College of Integrative Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
Qing LinThe Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, College of Integrative Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
Shanshan WangThe Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, College of Integrative Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
Feng LiShengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.
Minghan Huang *Department of Gastroenterology, the second people's Hospital affiliated to Fujian University of traditional Chinese Medicine, Fuzhou, 350001, Fujian province, China. huangminghan2010@163.com.
FangQin XueShengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China. xuefangqingsl@sina.com.
Yao LinThe Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, College of Integrative Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China. yaolin@fjtcm.edu.cn.

Funding

Fujian provincial health technology project 2021QNA001Fujian University of Traditional Chinese Medicine X2024037Joint Funds for the innovation of science and Technology,Fujian province 2023Y9292Joint Funds for the innovation of science and Technology,Fujian province 2024Y9486Major Science and Technology Project of Fujian Province 2024YZ034026National Science Foundation of China 82174365Natural Science Foundation of Fujian Province 2022J011015Natural Science Foundation of Fujian Province 2023J011166Rehabilitation technology innovation center by joint collaboration of ministry of education and Fujian province, Fujian University of Traditional Chinese Medicine X2022009-CollaborationYouth Research and Innovation Cultivation Program of Fujian Unveristy of Tradtional Chinese Medicine XQC2023007
6 · The paper itself

Abstract

Gastric cancer remains a leading cause of cancer-related mortality worldwide, characterized by poor prognosis due to its aggressive nature and high metastatic potential. While the E2-conjugating enzyme UBE2I (UBC9), essential for SUMOylation, has been implicated in various cancers, its precise role in gastric cancer remains poorly understood. In the study, we demonstrate significant UBC9 overexpression in gastric cancer tissues, which correlates with poor clinical outcomes. Functional analyses revealed that UBC9 knockdown significantly suppressed gastric cancer cell proliferation, migration, and invasion in vitro and in vivo, whereas UBC9 overexpression enhanced these malignant phenotypes. Through integrated transcriptomic and proteomic analyses, we identified ATF2 (Activating Transcription Factor 2) as a crucial downstream effector of UBC9-mediated oncogenic signaling. The mechanistic relationship between these factors was confirmed as ATF2 knockdown substantially attenuated the oncogenic effects of UBC9 overexpression. This newly identified UBC9-ATF2 regulatory axis promotes gastric cancer progression by enhancing cellular proliferation and metastatic potential. Our findings establish UBC9 and ATF2 as promising prognostic biomarkers and potential therapeutic targets, suggesting that intervention in the UBC9-ATF2 axis may provide novel therapeutic strategies for inhibiting gastric cancer progression and improving patient outcomes.

Indexed as

Activating Transcription Factor 2Biomarkers, TumorGene Expression Regulation, NeoplasticStomach NeoplasmsUbiquitin-Conjugating EnzymesAnimalsCell Line, TumorCell MovementCell ProliferationFemaleHumansMaleMiceMice, NudeNeoplasm InvasivenessPrognosisActivating Transcription Factor 2ATF2 protein, humanBiomarkers, TumorUbiquitin-Conjugating EnzymesUbiquitin-Conjugating Enzyme UBC9ATF2Gastric cancerPrognosisSUMOylationUBC9

Identifiers

PMID40635031
PMCPMC12243259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.